Heart Disease
Fibromyalgia
High Cholesterol Danger?
Toxic Metals
Free Radicals -- Primer
IV Chelation Therapy

Wrong Diet Causes Diabetes

Vibrant Life Home Web
Family Of Three Oral Chelation Formulas
The Wednesday Letter
The Hubbard Human Detoxification Program
Hopeless Diseases -- Invented to Sell Drugs
Wrong Relationship Cause of Disease

Brain Chemical Imbalance
Dr. Garry F. Gordon
Ultimate Resource On Chelation Therapy Home Page

Shopping Cart

Separate Search Page
or search below


Prevent Cancer

Oral Chelation Therapy
Other

Karl Loren's Policy On Psychiatric Drugs
Destruction Of American Education
Write To Karl Loren Table Of Contents

Evidence of MMPs Being Removed by Cysteine, EDTA and N Acetyl  Cysteine

Write To Karl Loren About This Page

Mention of EDTA and NAC as handling MMPs

 

 
 
(advertisement)

Central Sterile Corneal Ulceration

Last Updated: July 11, 2002

 
Synonyms and related keywords: neurotrophic ulcer, corneal ulcer, corneal stroma, corneal lesion, keratitis, corneal inflammation, stromal ulceration

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Author: C Stephen Foster, MD, FACS, Director of Immunology and Uveitis Service, Professor, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School

Coauthor(s): Joseph JK Ma, MD, Staff Physician, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary

 

C Stephen Foster, MD, FACS, is a member of the following medical societies: American Academy of Ophthalmology, American College of Rheumatology, American College of Surgeons, American Medical Association, American Society for Microbiology, Association for Research in Vision and Ophthalmology, and Royal Society of Medicine

 

Editor(s): Fernando H Murillo-Lopez, MD, Instructor, Department of Ophthalmology, Bolivian National Institute of Ophthalmology; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Christopher J Rapuano, MD, Co-Chairman of Refractive Surgery Department, Associate Professor, Cornea Service, Wills Eye Hospital, Jefferson Medical College; Ralph Garzia, OD, Assistant Dean for Clinical Programs, Associate Professor, School of Optometry, University of Missouri at St Louis; and Hampton Roy, Sr, MD, Clinical Associate Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Background: A corneal ulcer is defined as a lesion that involves degradation of the corneal stroma. This condition is associated with inflammation, either sterile or infectious. The primary purpose of this article is to highlight the pathogenesis of noninfectious stromal ulceration. The immune mechanisms of autoimmune ulcerative keratitis, particularly peripheral, are not included within this article.

 

Pathophysiology: An understanding of the pathophysiology of sterile corneal ulceration requires a review of the processes involved in epithelial and stromal wound healing, as well as an examination of the role of precorneal tear film, corneal nerves, proteolytic enzymes, and cytokines.

Epithelial wound healing

Corneal ulceration always begins with an epithelial defect. A persistent epithelial defect allows the corneal stroma to be exposed to the external environment and permits the process of stromal degradation.

Epithelial cell migration occurs centripetally until a defect is covered completely. Epithelial cells adjacent to the area of the defect flatten, lose their hemidesmosome attachments, and migrate on transient focal contact zones that are formed between cytoplasmic actin filaments and extracellular matrix proteins. Vinculin, integrin, fibronectin, fibrinogen, and fibrin are found in the region of these contact zones, which are formed continuously and cleaved to allow for cell migration. Plasmin is the protease responsible for cleaving fibrinogen and fibrin at these focal contact zones. The basement membrane is also important for epithelial migration, and abnormalities in basement membrane structure, whether due to trauma (eg, recurrent erosion syndrome) or dystrophy (eg, basement membrane dystrophy), can lead to persistence of corneal epithelial defects and stromal ulceration.

A sufficient supply of progenitor stem cells to facilitate epithelial cell proliferation is important for the cornea. A deficiency of limbal stem cells, either from disease (eg, aniridia) or trauma (eg, chemical burn), can preclude adequate epithelial wound healing, resulting in a persistent epithelial defect and allowing for stromal ulceration. Limbal stem cell transplantation (autograft, allograft, or ex vivo expansion) may be necessary in these cases.

Stromal wound healing

Stromal wound healing occurs via stromal keratocyte migration, proliferation, and deposition of extracellular matrix molecules, including collagen (specifically type III), adhesion proteins (eg, fibronectin, laminin), and glycosaminoglycans. These processes are facilitated by a phenotypic change among quiescent keratocytes to become active myofibroblasts, a task mediated by transforming growth factor beta (of presumptive epithelial origin).

Stromal necrosis and degradation

Matrix metalloproteinases (MMPs) are a group of structurally related endopeptidases that require a metal cofactor. To date, 20 such enzymes have been identified and are categorized according to their substrate specificity. The main function of metalloproteinases is to degrade extracellular matrix and basement membrane components. With respect to corneal wound healing and ulceration, MMP-1, MMP-2, MMP-8, and MMP-9 appear to be the most important. MMP-2 and MMP-9 are known as gelatinases and are involved in cleaving collagen types IV, V, VII, and X, as well as fibronectin, laminin, elastin, and gelatins. MMP-1 and MMP-8 are involved in cleaving collagen types I, II, and III. Metalloproteinases are secreted as proenzymes by neutrophils, injured epithelial cells, and keratocytes. They are activated by proteolytic cleavage of the N-terminal region in the extracellular compartment. In vivo, tissue inhibitors of metalloproteinases (TIMPs) inhibit collagenase activity.

MMP-9 is expressed by basal (replicating) epithelium and is thought to be important in the degradation of the basement lamina. In chemical injuries, this step always precedes the degradation of stromal extracellular matrix by MMP-1 and MMP-8. The collagenolytic activity of these latter enzymes reach a nadir of activity at approximately 3 weeks following injury, a time frame that parallels the peak of collagen synthesis activity in an alkali burn animal model. A relatively higher degree of collagenolysis relative to synthesis is thought to result in degradation, progressive corneal thinning, and, hence, ulceration of the corneal stroma. In vivo, this balance is moderated by cytokines secreted by the epithelium, stromal keratocytes, and inflammatory cells.

Since all metalloproteinase enzymes require metal cofactors Ca2+ and Zn2+, such chelating agents as ethylenediaminetetraacetic acid (EDTA), acetylcysteine, and penicillamine inhibit collagenase activity. Tetracyclines also possess anticollagenolytic activity. Endogenous TIMPs and alpha2-macroglobulin have metalloproteinase inhibitory activity and are probably the main inhibitors of MMPs in vivo.

The role of corneal nerves

The cornea is densely innervated by fibers of the ophthalmic division of the trigeminal nerve and sympathetic nerve fibers from the superior cervical ganglion. The corneal epithelium is supplied by approximately 1000 small axons. Decreased corneal sensation from denervation can result in stromal ulceration and perforation. A decrease in tearing, protective reflexes, and blink rate are associated with decreased corneal sensation.

In 1954, the classic experiment by Sigelman et al demonstrated that ocular surface changes associated with neurotropic keratitis in denervated animals persist despite tarsorrhaphy, suggesting a trophic effect of corneal nerves. The exact mechanism of this trophic effect is not definitively known. Evidence suggests that sensory neuron loss leads to a severe depletion of acetylcholine in an otherwise acetylcholine rich tissue, resulting in a relative decrease in epithelial cell growth. Other studies attributed the depletion of substance P associated with sensory denervation as the cause of the changes associated with neurotrophic keratitis. Recent clinical trials of nerve growth factor (NGF) by Bonini et al demonstrated a beneficial effect in promoting corneal epithelial wound healing and possibly improving sensitivity in patients with neurotrophic keratitis.

The role of the precorneal tear film in ulceration

The exposure of the bare corneal stroma to its environment secondary to deficient or impaired epithelial wound healing is thought to contribute to stromal degradation through environmental factors, cytokines, lytic enzymes, and neutrophils in the tear film. Direct neutrophil adhesion to the corneal stroma theoretically allows hydrolytic and collagenolytic enzymes, including MMP-8 (neutrophil collagenase), to contribute to the degradation of the corneal stromal extracellular matrix. Dohlman et al and subsequently Kenyon et al demonstrated that a glued on methylacrylate lens applied to a rabbit alkali burn model of corneal ulceration protected the stroma from collagenolysis by neutrophils and injured epithelial cells. Keratocyte fibroblasts also may contribute to this milieu. The prevention of neutrophil infiltration and promotion of epithelialization is thought to be at least one of the mechanisms responsible for the beneficial effect of amniotic membrane graft use in preventing stromal ulceration.

In addition, cytokines, such as hepatocyte growth factor (HGF), keratocyte growth factor (KGF), and epidermal growth factor (EGF), are produced by the lacrimal gland and, thus, are present in tears. HGF is upregulated in response to corneal injury in parallel with increased aqueous tear production. In the wounded cornea, these cytokines may play an important role in regulating epithelial healing. Inflammatory cytokines, including interleukin 1 (IL-1) alpha, are detectable in normal human tears and may be important in causing further degradation of the corneal stroma either directly by inducing keratocyte apoptosis or by recruiting inflammatory cells via their chemotactic properties. In addition, an irregular tear film and a decreased tear film breakup time over the area of the bare stroma can cause a delle effect that may contribute to an unfavorable cellular environment for the viability and proliferation of stromal keratocytes.

The role of cytokines

The complex autocrine and paracrine functions of the cytokines involved in the interactions between the corneal epithelium and stromal keratocytes are important in achieving the appropriate responses to corneal wound healing. These responses are orchestrated by complex interactions between the cytokines secreted by each of these cell types. While their precise triggers and interactions are still being elucidated, cytokines can induce and mediate many of the fundamental steps involved in wound healing.

Epithelial cell migration, proliferation, and differentiation are influenced by the stromal keratocyte cytokines, KGF and HGF. The cornea is not unique with respect to the stromal-epithelial interactions of these 2 cytokines, which are mediators of similar interactions in the breast, skin, and lung. Although the expression profiles of these cytokines lend themselves toward a linear interpretation of their stromal-epithelial interactions, these cytokines clearly are modulated further in vivo by the effects of other cytokines and truncated receptors of these molecules.

In what is likely to be merely the tip of the iceberg with respect to the understanding of cytokine-cytokine interactions, both KGF and HGF mRNA production are altered by the fibroblast cytokines, EGF, transforming growth factor alpha, platelet-derived growth factor (PDGF), and IL-1. In addition, EGF, PDGF, IL-1 alpha, interleukin 6 (IL-6), and tumor necrosis factor (TNF) at low concentrations appear to enhance fibronectin (FN)-induced epithelial cell migration.

Not to be eclipsed by stromal influences, epithelial cells modulate important keratocyte responses to epithelial cell injury. Keratocyte wound healing processes, including MMP production and regulation, HGF and KGF production, and keratocyte apoptosis, are mediated via various cytokines, including IL-1 and soluble Fas ligand. Anterior stromal keratocyte cell death is an important feature of corneal wounding and stromal degradation.

Beyond keratocyte cell death caused by mechanical injury or necrosis associated with neutrophil infiltration, IL-1– and Fas ligand–mediated apoptosis is an important stromal response to epithelial injury. Since both of these cytokines can be produced by keratocytes, autocrine modulation of these responses may occur. IL-1 and PDGF also regulate MMP expression in stromal keratocytes. The exact keratocyte response to IL-1 is likely to be determined by the cytokine milieu in which the targeted keratocyte resides. Other cytokine systems that have demonstrated fibroblast apoptosis include TNF and bone morphogenic protein (BMP).

Meticulous control of these cytokines conceivably allows for more predictable corneal wound healing. Topical KGF has been shown to accelerate epithelial wound healing in a rabbit model of corneal ulceration. Since its effects are mediated through a paracrine pathway, topical use of cytokines (eg, KGF) may prove to be especially effective in ocular disorders accompanied by loss of epithelium that require corneal limbal stem cell proliferation.

Cytokines and trophic factors from corneal nerves, the tear film, the conjunctiva, conjunctival vessels, the endothelium, and the anterior chamber may have important modulating effects on corneal epithelial and stromal healing responses and, thus, corneal ulceration.

 

Frequency:
 

  • In the US: The incidence rate depends on the etiology of the corneal ulcer.

Mortality/Morbidity: Corneal scarring, decreased vision, neovascularization, perforation, and blindness are associated with this condition.

Sex: Because of an increased incidence of injuries, this condition may be seen more frequently in males than females.

  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

History:

  • In diagnosing this condition, differentiating between infectious and noninfectious etiologies is crucial. Since the clinical management of any corneal ulcer is dependent on its etiology, obtaining all of the salient factors (eg, endogenous, exogenous, local) is important. Therapies for sterile persistent ulcerations should be considered only after adequately addressing infectious and systemic factors.
  • Key points to assess in obtaining the history of a patient with a corneal ulcer include the following:
    • Prior ocular history - Prior ocular and adnexal surgery, recurrent episodes or infections (eg, herpes), and corneal dystrophy
    • Past medical history - Immune status, collagen vascular diseases, systemic infections, diabetes, malnutrition, alcoholism, and chronic debilitating diseases
    • History of trauma - Foreign bodies and their origin (eg, soil, vegetation, water), chemical splashes, and lid lacerations
    • Contact lens use - Type, frequency, duration, overnight use, and hygiene
    • Medications - Ocular and otherwise
    • History of present illness - Duration, ocular symptoms (eg, degree of pain vs clinical impression), and chronicity
    • Social history - Patient from an area endemic for certain infectious processes, nutritional status, and any alcohol abuse
  • The etiology of a sterile ulcer is often multifactorial; in this setting, identifying the coconspirators in this process is important. A thorough evaluation to identify potential factors, including medications (medicamentosa), impaired corneal sensation (neurotrophic), exposure (eg, lagophthalmos), and reduced tear production (sicca), is necessary in most cases of persistent noninfectious ulceration.

Physical:

  • The physical examination should begin with a gestalt impression of the entire patient, with attention to the following:
    • General health of the patient - Skin lesions, skeletal abnormalities, mental status, degree of discomfort, hearing aids, scars, and limitations to ambulation that may indicate a systemic illness
    • Local ocular adnexa and related organs - Eyelids, lacrimal system, blink rate, scars, mucous membranes (eg, lips/mouth, conjunctiva), orbit, symmetry, and evidence of inflammation or infection
    • Palpation - If indicated for orbital resiliency (thyroid/exposure), lymphadenopathy, and lacrimal or other adnexal masses
    • Observation - Lagophthalmos and blink rate
    • Assessment of vital signs of the eye - Visual function, corneal sensation, tonometry, pupil function, and motility of the eye (Corneal sensation should be checked prior to tonometry.)
  • On slit lamp examination of the cornea, note the appearance of and evaluate the following:
    • Conjunctiva, sclera, and lids - Erythema, pattern of injection (ciliary flush, diffuse or deep), perilimbal nodules, discharge, lid closure, lid margin disease, and flipped upper lid to exclude foreign body and floppy eyelid syndrome
    • Tear film - Degree, symmetry, regularity, and presence of debris
    • Epithelium - Location of epithelial defect (localized or diffuse), regularity, and microcysts
    • Stroma - Thinning and presence/pattern of infiltrates (eg, ring, feathery, radial)
    • Endothelium - Keratic precipitates
    • Anterior chamber - Hypopyon and inflammation
    • Corneal sensation
    • Symmetry between the eyes
    • Fluorescein examination
    • Dilated examination (if necessary)

Causes: A thorough history and physical examination should allow a clinician to narrow down the differential diagnosis.

  • Infectious causes (which need to be ruled out first) include the following:
    • Bacterial (focal infiltrate)

       

    • Fungal (vegetable matter, eg, branch; appearance of satellite lesions; feathery borders to infiltrate; chronic)

       

    • Acanthamoeba (contact lens wear, tap water, soil, severe pain out of proportion to the appearance, radial keratitis, ring ulcer)

       

    • Herpes simplex virus (history, dendrites, decreased sensation, disciform keratitis, increased intraocular pressure)
    • Herpes zoster virus (vesicles over dermatome; pseudodendrites, no true terminal bulbs; decreased sensation; increased intraocular pressure)

       

    • Contact lens related (infectious or noninfectious)
  • Noninfectious causes include the following:
    • Chemical burns, including alkali/acid burn (check pH)

       

    • Thermal/radiation burns (history)

       

    • Sicca (filaments, Sjögren syndrome)

       

    • Neurotrophic (decreased sensation, may have minimal pain, rolled edges, oval, lower one half of cornea, may be quite thin, herpes zoster virus/herpes simplex virus, postsurgery)
    • Exposure (lagophthalmos, lid abnormalities, inadequate blink, facial palsy, proptosis, thyroid disease)

       

    • Medicamentosa (drops)

       

    • Atopic (history, follicles/papillae)

       

    • Basement membrane abnormalities (microcysts, evidence of map-dot-fingerprint or anterior stromal dystrophies, history of trauma, other dystrophy)

       

    • Factitious
  • Immune-related causes (usually peripheral) include the following:
    • Wegener granulomatosis
    • Rheumatoid arthritis
    • Other collagen vascular diseases (indicated from history and associated systemic findings)
  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Corneal Abrasion
Corneal Erosion, Recurrent
Corneal Melt, Postoperative
Dry Eye Syndrome
Herpes Simplex
Herpes Zoster
Keratitis, Bacterial
Keratopathy, Neurotrophic
Sjogren Syndrome
Ulcer, Corneal
 


 

 
  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Lab Studies:
 

  • Given the morbidity of missing an infectious ulcer, the importance of performing corneal smears and cultures cannot be overemphasized. Infectious etiologies should be ruled out initially by performing smears and cultures.
  • Corneal scraping also is indicated to evaluate for infectious etiologies.
  • Perform a workup to rule out infectious or systemic inflammatory diseases (eg, collagen vascular, autoimmune) as clinically indicated. Systemic testing (eg, blood work) may be necessary in certain patients.
  • The precise stains and cultures depend on clinical suspicion.
    • Stains - Gram stain, Giemsa, Calcofluor white, acid-fast bacillus (AFB), and Gomori
    • Cultures - Sabouraud agar, blood/chocolate agar, thioglycolate solution, and Page solution (then Escherichia coli overlay)

Procedures:
 

  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Medical Care: Individual treatment should be tailored toward the coconspirators that are identified by the history and physical examination. Again, the importance of first excluding infectious etiologies is paramount. Once identified, each contributing factor needs to be treated appropriately. All toxic drops should be eliminated if medicamentosa is suspected. Lagophthalmos should be treated with copious lubrication, with taping for variable amounts of time, beginning with sleeping hours. Tarsorrhaphy is indicated if previous method fails. Patients with sicca need copious lubrication and punctal plugs. Evaluate these patients for systemic rheumatologic disease if suspected by clinical history or examination. If immune disease is suspected, systemic immunomodulatory therapy may be necessary. Treatment modalities are outlined below.

  • Antibiotics are used to treat the ulcer or as a prophylactic but do encourage resistant microbial strains. Long-term use with certain antibiotics may cause medicamentosa, epitheliopathy, and crystal deposits.
  • Immunomodulatory medications (eg, cyclophosphamide, cyclosporine, methotrexate, azathioprine) are indicated if necessary. Topical cyclosporin A drops currently are being evaluated in clinical trials.

     

  • Lubrication (eg, artificial tears) is recommended but avoid preservatives.
  • For chemical burns, corticosteroids (ie, prednisone) are useful for reducing surface inflammation; however, after 10-14 days, collagen synthesis becomes important in the repair process. Prednisone may alter the balance of collagen synthesis versus degradation. Although they have weaker anti-inflammatory properties, progestational steroids (eg, medroxyprogesterone) demonstrate less suppression of collagen synthesis (wound repair).

     

  • Medroxyprogesterone (eg, Provera)

     

  • Use of vitamin A is investigational. Initial trials demonstrated clinical efficacy that was not replicated subsequently.

     

  • Although investigational, fibronectin has been shown to improve epithelialization in vitro; however, clinical trials did not demonstrate efficacy.

     

  • Use of ascorbic acid/citrate for burns only is investigational.

     

  • Serum derived tears are under investigation.

     

  • Cell proliferation and trophic factors (eg, KGF, EGF, NGF) are investigational.
  • Metalloproteinase inhibitors
    • Synthetic thiols

       

    • N-acetylcysteine

       

    • Cysteine

       

    • Sodium and calcium EDTA

       

    • Penicillamine

       

    • Tetracyclines

       

    • TIMPs
  • Punctal occlusion includes plugs/cautery.

     

  • A primary barrier method (eg, therapeutic soft contact lenses, scleral lenses, glued on contact lens) should be created and used.

     

  • Tissue adhesives are best for impending or actual perforations that are 1 mm or smaller in size. They may be removed or allowed to extrude spontaneously after 6-8 weeks when a fibrovascular scar has formed and eliminated the risk of stromal ulceration.

     

  • Amniotic membrane transplantation (alone or with ex vivo expansion or limbal stem cell transplantation)

     

  • Conjunctival flap/graft or Tenon-plasty (for reestablishment of limbal vascularization in alkali burns)

     

  • Tarsorrhaphy (temporary vs permanent lateral)

     

  • Corneal transplant (lamellar or penetrating) or tectonic graft (temporizing measure until graft bed is vascularized and arrests further ulceration)

     

  • Mucous membrane grafting

     

  • Keratoprosthesis

Surgical Care: See Medical Care for possible surgical treatments.

Consultations:

  • Corneal specialists
  • Neurologist or neuro-ophthalmologist for probable CNS neurotrophic etiology
  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

As discussed in Medical Care, a number of medications for sterile corneal ulcers refractory to conventional treatment are currently being investigated with respect to their clinical efficacy (eg, fibronectin, vitamin A, ascorbic acid, serum-derived tears, metalloproteinase inhibitors, neurotrophic growth factor). Therefore, standard dosing, indications, treatment regimens, and contraindications with respect to these medications are not available. The authors recommend that interested physicians directly contact clinical investigators for specific treatment regimens currently employed in treatment trials.

Antibiotics often are used prophylactically in treating patients with sterile corneal ulcerations. Specific dosing and medication information on topical antibiotics are not included in this article.

Immunomodulatory treatment regimens are complex, and elaborating on medication dosing and treatment regimens for specific rheumatologic diseases is beyond the scope of this article.
 

Drug Category: Ophthalmic corticosteroids -- Minimize the activity of inflammatory cells and formation of granulomas. Used in symptomatic patients and commonly provides symptomatic improvement.

Drug Name
 
Prednisolone (AK-Pred, Pred Forte, Pred Mild, Inflamase Forte) Suspension 0.12% -- Decreases inflammation and corneal neovascularization. Suppresses migration of polymorphonuclear leukocytes and reverses increased capillary permeability.
Adult Dose 1gtt q1-12h, taper
Pediatric Dose Not established
Contraindications Documented hypersensitivity; viral, fungal, or tubercular infections
Interactions None reported
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Known to cause cataract formation with long-term use; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use (obtain fungal cultures when appropriate); safety in lactation unknown
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Further Outpatient Care:
 

  • Patients must receive close follow-up care until resolution of the corneal ulcer.

Deterrence/Prevention:
 

  • Patients should wear eye protection to prevent injury to the cornea, especially if the cornea is thin.

Complications:
 

  • Complications include corneal scarring, neovascularization, decreased vision, central corneal perforation, and endophthalmitis. Other possible complications include cataract, glaucoma, and blindness.

Prognosis:
 

  • Prognosis depends on the severity of the condition and patient response to therapy in addition to associated local and systemic factors.
  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

Medical/Legal Pitfalls:
 

  • Failure to promptly diagnose and provide early treatment to prevent visual loss
  • Failure to first rule out infectious causes

Special Concerns:
 

  • In treating a patient with a corneal ulcer, evaluate for underlying systemic conditions and manage them appropriately.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography
 

  • Albert DM, Jakobiec FA, eds: In: Principles and Practice of Ophthalmology. 2nd ed. Boston: WB Saunders Co; 2000.
  • Barletta JP, Angella G, Balch KC, et al: Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor. Invest Ophthalmol Vis Sci 1996 Jan; 37(1): 20-8[Medline].
  • Bernauer W, Ficker LA, Watson PG, Dart JK: The management of corneal perforations associated with rheumatoid arthritis. An analysis of 32 eyes. Ophthalmology 1995 Sep; 102(9): 1325-37[Medline].
  • Bonini S, Lambiase A, Rama P: Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology 2000 Jul; 107(7): 1347-51; discussion 1351-2[Medline].
  • Dohlman CH, Slansky HH, Laibson PR, et al: Artificial corneal epithelium in acute alkali burns. Ann Ophthalmol 1969; 112.
  • Dua HS, Gomes JA, Singh A: Corneal epithelial wound healing. Br J Ophthalmol 1994 May; 78(5): 401-8[Medline].
  • Geerling G, Joussen AM, Daniels JT, et al: Matrix metalloproteinases in sterile corneal melts. Ann N Y Acad Sci 1999 Jun 30; 878: 571-4[Medline].
  • Gipson IK, Inatomi T: Extracellular matrix and growth factors in corneal wound healing. Curr Opin Ophthalmol 1995 Aug; 6(4): 3-10[Medline].
  • Imanishi J, Kamiyama K, Iguchi I, et al: Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000 Jan; 19(1): 113-29[Medline].
  • Kaufman HE, et al, eds: The Cornea. 2nd ed. Boston: Butterworth-Heinemann; 1998.
  • Kenyon KR, Berman M, Rose J: Prevention of stromal ulceration in the alkali-burned rabbit cornea by glued-on contact lens. Evidence for the role of polymorphonuclear leukocytes in collagen degradation. Invest Ophthalmol Vis Sci 1979 Jun; 18(6): 570-87[Medline].
  • Sigelman S, Friedenwald JS: Mitotic and wound healing activities of the corneal epithelium: effect of sensory denervation. Arch Ophthalmol 1954; 52.
  • Wilson SE, Liu JJ, Mohan RR: Stromal-epithelial interactions in the cornea. Prog Retin Eye Res 1999 May; 18(3): 293-309[Medline].

 

NOTE:
Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER

Central Sterile Corneal Ulceration excerpt

© Copyright 2002, eMedicine.com, Inc.

 

 


Special Pages On The Various of 19 Web Sites Authored by Karl Loren
OC History Oral Chelation Testimonials
Family Of Three Oral Chelation Formulas Life Glow Basic Life Glow Basic Ingredient List
Life Glow Plus Life Glow Plus
Ingredient List
American Heart Association -- Lies
Super Life Glow Super Life Glow
 Ingredient List
FAQ
All Products Shopping Cart Order Section Research
Taheebo Life Tea Witch Doctors Versus Harvard MSM Sulfur
Calcium How Bones Grow Colloidal Minerals
Jean Ross Philosophy The Wednesday Letter
Arthritis & James Coburn's Use Of MSM Karl Loren Viewpoints News And Announcements
Dr. Flanagan's Microhydrin 500 Page Book On Heart Disease Colostrum & Transfer Factor
Germanium Ultrasound Technology Bulk MSM
Cancer & Biopsy Diabetes Heart Disease & Bypass Surgery
Karl Loren's Diet Guarantee High Cholesterol Risk?
The Links Below Jump To Pages On Whatever Web You Are In
Table Of Contents Search This Web Navigation Help Page
Write To Karl Loren -- He Pledges To Answer EVERY Personal Message, Personally.  Click here or on his name in the box below.
The Links Below Are To Various Web Sites Published By Karl Loren
Karl Loren Web Vibrant Life Web Karl Loren's Book
Super Colostrum Bulk MSM Heart Disease
Emmessar Happiness Arthritis
Instead Of Chelation Therapy Super Colostrum (2)
Immune Egg Central Page For All 19 Webs!
 

I promise to answer your message -- click here to send me a personal message

Dear Karl,                                        

 

 

 

 

SUBSCRIBE:  The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.  You can view more than 50 back issues of this publication by clicking here.  The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.  It is automatically published on the Tuesday night just before the first Wednesday of every month.  You can subscribe to this free monthly electronic letter by entering your eMail address and name below.  You will then automatically receive a request for confirmation, sent to whatever address you have entered.  If you do NOT receive this confirmation request, then you will not be subscribed.  There may have been an error with your address and you should resubmit.  The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.  When you receive this confirmation request you must reply to it, or your subscription will not become active.  No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.

E-Mail Address:
First Name:
Last Name:

REMOVAL:  You can remove yourself from the subscription list in several different ways.  Click here to read about this entire newsletter system.  Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.  If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.  Thus, no one else can unsubscribe you, from some other computer, without your knowledge.  But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.

E-Mail Address:

Personal Message:  When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.  Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.  You can select particular information you would like to receive, along with the free cassette tape and catalog.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.  Within the US and Canada, use the toll free number:  (800) 523-4521, the local number:  (818) 558-1799, the FAX:  (818) 558-7299, eMail to kimberly@oralchelation.com or any one of the hundreds of message forms throughout the 50 web sites.  Vibrant Life normally ships the same day we get an order.  There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.  Check out our companion site, at:  http://www.oralchelation.net where Karl's 2000 page book is published.  Karl Loren is the author and webmaster for this BOOK, as well as for another web site about ORAL CHELATION.  His personal philosophical articles are at PHILOSOPHY

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.  Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:  One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site.  This permission does not extend to materials on this site which are copyrighted by others.